Latest Capital Raising And Placements News

Silver Mines Limited progresses regulatory approvals for its flagship Bowdens Silver Project in NSW, secures $34 million through capital raising, and acquires promising US exploration assets, setting the stage for growth.

Biotron Limited has advanced its Hepatitis B antiviral program while preparing to acquire Sedarex Limited, backed by a $2.5 million capital raise. The move signals a strategic expansion into safer anaesthetics alongside ongoing R&D progress.

Lithium Universe Limited has raised $2.5 million through a placement to advance its lithium refinery in Québec and innovative solar panel recycling technology. The funding highlights investor confidence in the company’s dual strategy to close North America’s lithium supply gap and pioneer sustainable metal recovery.

Brazilian Rare Earths Limited has raised A$120 million through a share placement to fast-track its high-grade rare earth projects and integrated refinery development in Brazil.

INOVIQ Limited has launched an A$11.5 million capital raise to fast-track clinical validation and commercialization of its ovarian cancer screening test and advance its CAR-exosome therapeutic program targeting solid tumors.

ClearVue Technologies has raised A$4.6 million in a strongly supported placement to accelerate international certification and ongoing innovation of its solar façade products.

Prescient Therapeutics has bolstered its cash reserves to $12.3 million following a $9.8 million capital raise, while progressing its PTX-100 cancer therapy through global Phase 2 trials with encouraging early lymphoma results.

Arafura Rare Earths has successfully raised $9.83 million through an upsized Share Purchase Plan, well above its $5 million target, boosting total capital raised this year to nearly $90 million.

Orion Minerals has raised A$5 million through a share placement to fund early development at its Prieska Copper Zinc Uppers mine and advance studies at the Okiep Copper Project, underpinning its transition towards production.

VEEM Ltd has secured $14 million through a placement to fuel its expansion in defence manufacturing, including a landmark US$33 million licence agreement with Northrop Grumman. The company is poised to accelerate revenue in the second half of FY26 as it deepens ties with major US defence contractors.

Alterity Therapeutics has raised A$20 million through a strategic placement to advance its promising ATH434 treatment for Multiple System Atrophy, backed by encouraging Phase 2 trial results. The capital injection strengthens the company’s balance sheet as it prepares for regulatory discussions with the FDA.

The Hydration Pharmaceuticals Company Limited reported a 55% reduction in half-year losses to $1.44 million, driven by strategic cost reductions and a sharpened focus on US e-commerce operations. Despite a 15% revenue decline, the company is banking on new product launches and retail expansion to fuel growth.